The Food & Drug Administration has paved the way for a phase I/II study of the company's Clevegen drug Stateside
Open Orphan reversed into Venn Life Sciences in June 2019
Summit Therapeutics' potential breakthrough targets C.difficile
"We have eleven programmes, of which three three are relatively near term for licensing," said...
With the result of the 12 December election still uncertain, the three most likely results could...
hVIVO PLC's (LON:HVO) Dr Trevor Phillips caught up with Proactive London's Andrew Scott following the news they're to merge with Open Orphan PLC (LON:ORPH). Open Orphan intends to maintain the existing research and development activities of hVIVO, relative to supporting hVIVO's clinical...
Get our market previews and stories before the main networks.
Not just the FTSE. Read about
opportunities from the whole
Hear directors at first-hand
or meet them in person at our events.
Watch IPOs and access on the same terms as the institutions.